Epizyme Announces Removal of FDA’s Partial Ban in Phase II Clinical TrialsAllbiopro2018-09-25T11:10:45+09:009월 25th, 2018|
Aridis Pharma Deepens Patents for Infectious Disease TherapiesAllbiopro2018-09-25T11:09:53+09:009월 25th, 2018|
Two-Faced: How to Deal with the Co-Worker Who Stabs You in the BackAllbiopro2018-09-25T11:09:03+09:009월 25th, 2018|
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramAllbiopro2018-09-25T11:08:11+09:009월 25th, 2018|
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)Allbiopro2018-09-25T11:07:18+09:009월 25th, 2018|
With its hepatitis C franchise tumbling, Gilead plots knockoffs of its own drugsAllbiopro2018-09-25T11:06:25+09:009월 25th, 2018|
AstraZeneca CEO Pascal Soriot bemoans being one of the ‘lowest-paid’ CEOs in pharmaAllbiopro2018-09-25T11:05:33+09:009월 25th, 2018|
Believe it: Just as Amarin promised, Vascepa delivers big win in heart-risk studyAllbiopro2018-09-25T11:04:40+09:009월 25th, 2018|
AstraZeneca steps up its Farxiga game with CV outcomes winAllbiopro2018-09-25T11:03:49+09:009월 25th, 2018|
Alexion eyes $500M-plus in new Soliris sales with latest rare-disease winAllbiopro2018-09-25T11:02:57+09:009월 25th, 2018|
With positive phase 2 data, Akcea, Ionis could pocket $150M from NovartisAllbiopro2018-09-25T11:01:16+09:009월 25th, 2018|
AnaptysBio’s lead IL-33 antibody clears midstage test in asthmaAllbiopro2018-09-25T11:00:24+09:009월 25th, 2018|
Nightstar posts early-phase data on retinal gene therapyAllbiopro2018-09-25T10:58:40+09:009월 25th, 2018|
Sarepta DMD gene therapy hold lifted in ‘record time’Allbiopro2018-09-25T10:57:49+09:009월 25th, 2018|
Former Merck clinical research VP Arthur Santora joins Entera Bio as CMOAllbiopro2018-09-25T10:56:06+09:009월 25th, 2018|
